Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CheckMate -743, a phase III trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival.

Bristol-Myers Squibb sponsors both drugs.

Based on a prespecified interim analysis conducted by the independent data monitoring committee, Opdivo in combination with Yervoy resulted in a statistically significant and clinically meaningful improvement in OS compared to chemotherapy (pemetrexed and cisplatin or carboplatin).

The safety profile of Opdivo plus Yervoy observed in the trial reflects the known safety profile of the combination.

“These topline results from the CheckMate-743 trial demonstrate the potential of Opdivo plus Yervoy in previously untreated patients with malignant pleural mesothelioma, and is another example of the established efficacy and safety of the dual immunotherapy combination seen in multiple tumor types,” Sabine Maier, development lead of Thoracic Cancers at BMS, said in a statement.

CheckMate-743 is an open-label, multi-center, randomized phase III trial evaluating Opdivo plus Yervoy compared to chemotherapy (pemetrexed and cisplatin or carboplatin) in patients with previously untreated malignant pleural mesothelioma. The primary endpoint of the trial was OS. Secondary endpoints included objective response rate, disease control rate, progression-free survival, and efficacy measures according to PD-L1 expression level.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login